Does the use of targeted agents in advanced gastroesophageal cancer increase complete response? A meta-analysis of 18 randomized controlled trials

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• DavidsonMOkinesAFStarlingNCurrent and future therapies for advanced gastric cancerClin Colorectal Cancer201514423925026524924
   PubMed Web of Science ®Google Scholar
• KimHSKimHJKimSYSecond-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysisAnn Oncol201324112850285423942775
   PubMed Web of Science ®Google Scholar
• JanowitzTThuss-PatiencePMarshallAChemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level dataBr J Cancer2016114438138726882063
   PubMed Web of Science ®Google Scholar
• ShahMAUpdate on metastatic gastric and esophageal cancersJ Clin Oncol201533161760176925918288
   PubMed Web of Science ®Google Scholar
• WaddellTVerheijMAllumWCunninghamDCervantesAArnoldDGastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-upEur J Surg Oncol201440558459124685156
   PubMed Web of Science ®Google Scholar
• PriceTJShapiroJDSegelovEManagement of advanced gastric cancerExpert Rev Gastroenterol Hepatol20126219920922375525
   PubMed Web of Science ®Google Scholar
• TomaselloGGhidiniMLiguigliWRattiMToppoLPassalacquaRTargeted therapies in gastric cancer treatment: where we are and where we are goingInvest New Drugs201634337839326873643
   PubMed Web of Science ®Google Scholar
• YaziciOSendurMAOzdemirNAksoySTargeted therapies in gastric cancer and future perspectivesWorld J Gastroenterol201622247148926811601
   PubMed Web of Science ®Google Scholar
• WangCWFangXHThe role of targeted agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trialsEur Rev Med Pharmacol Sci20162091725173227212163
   PubMed Web of Science ®Google Scholar
• CilibertoDStaropoliNCagliotiFA systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?Cancer Biol Ther20151681148115926061272
   PubMed Web of Science ®Google Scholar
• ZhaoTTXuHXuHMThe efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trialsGastric Cancer201821336137129455269
   PubMed Web of Science ®Google Scholar
• JanmaatVTSteyerbergEWvan der GaastAPalliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancerCochrane Database Syst Rev201711CD00406329182797
   PubMedGoogle Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPLoS Med200967e100009719621072
   PubMed Web of Science ®Google Scholar
• MoherDCookDJEastwoodSOlkinIRennieDStroupDFImproving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analysesLancet199935491931896190010584742
   PubMed Web of Science ®Google Scholar
• CheyneWWAn Address ON ACUTE ABDOMINAL SYMPTOMS: Delivered before the Walthamstow Division of the Metropolitan Counties Branch of the British Medical AssociationBr Med J1905123201313131620762161
   PubMedGoogle Scholar
• ZintzarasEIoannidisJPHeterogeneity testing in meta-analysis of genome searchesGenet Epidemiol200528212313715593093
   PubMed Web of Science ®Google Scholar
• DersimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials1986731771883802833
   PubMedGoogle Scholar
• BeggCBMazumdarMOperating characteristics of a rank correlation test for publication biasBiometrics1994504108811017786990
   PubMed Web of Science ®Google Scholar
• EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ199731571096296349310563
   PubMed Web of Science ®Google Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials19961711128721797
   PubMedGoogle Scholar
• BangYJvan CutsemEFeyereislovaATrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLancet2010376974268769720728210
   PubMed Web of Science ®Google Scholar
• OhtsuAShahMAvan CutsemEBevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III studyJ Clin Oncol201129303968397621844504
   PubMed Web of Science ®Google Scholar
• LordickFKangYKChungHCCapecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trialLancet Oncol201314649049923594786
   PubMed Web of Science ®Google Scholar
• OhtsuAAjaniJABaiYXEverolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 studyJ Clin Oncol201331313935394324043745
   PubMed Web of Science ®Google Scholar
• WaddellTChauICunninghamDEpirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialLancet Oncol201314648148923594787
   PubMed Web of Science ®Google Scholar
• FuchsCSTomasekJYongCJRamucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialLancet20143839911313924094768
   PubMed Web of Science ®Google Scholar
• ShenLLiJXuJBevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)Gastric Cancer201518116817624557418
   PubMed Web of Science ®Google Scholar
• WilkeHMuroKvan CutsemERamucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialLancet Oncol201415111224123525240821
   PubMed Web of Science ®Google Scholar
• DuFZhengZShiSS-1 and cisplatin with or without nimotuzumab for patients with untreated unresectable or metastatic gastric cancer: a randomized, open-label phase 2 trialMedicine20159423e95826061330
   PubMed Web of Science ®Google Scholar
• ShahMABangYJLordickFEffect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trialJAMA Oncol20173562062727918764
   PubMed Web of Science ®Google Scholar
• CatenacciDVTTebbuttNCDavidenkoIRilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncol201718111467148228958504
   PubMed Web of Science ®Google Scholar
• BangYJXuRHChinKOlaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trialLancet Oncol201718121637165129103871
   PubMed Web of Science ®Google Scholar
• YoonHHBendellJCBraitehFSRamucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trialAnn Oncol201627122196220327765757
   PubMed Web of Science ®Google Scholar
• ShahMAChoJYTanIBA randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced adenocarcinoma of the stomach and gastroesophageal junctionOncologist20162191085109027401892
   PubMed Web of Science ®Google Scholar
• PavlakisNSjoquistKMMartinAJRegorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trialJ Clin Oncol201634232728273527325864
   PubMed Web of Science ®Google Scholar
• MoehlerMGepfner-TumaIMadererASunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker programBMC Cancer20161669927582078
   PubMed Web of Science ®Google Scholar
• LiJQinSXuJRandomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionJ Clin Oncol201634131448145426884585
   PubMed Web of Science ®Google Scholar
• HechtJRBangYJQinSKLapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC – a randomized phase III trialJ Clin Oncol201634544345126628478
   PubMed Web of Science ®Google Scholar
• TekerFCanbazFKemalYYucelIA case of gastric cancer with liver metastases had a complete response with cisplatin and capecitabine as third-line chemotherapyJ Cancer Res Ther20151141026
   PubMed Web of Science ®Google Scholar
• ToyokawaTOhiraMSakuraiKLong-term survival with complete remission after hepatic arterial infusion chemotherapy for liver metastasis from gastric cancer: a case reportWorld J Surg Oncol20151326826336890
   PubMed Web of Science ®Google Scholar
• IzuishiKKobayashiMSanoTMoriHEbaraKPathological complete response and long-term survival in a very elderly patient after neoadjuvant chemotherapy for locally advanced, unresectable gastric cancerCase Rep Oncol Med2014201453292453292525298899
   PubMedGoogle Scholar
• GallagherDJKemenyNMetastatic colorectal cancer: from improved survival to potential cureOncology2010783–423724820523084
   PubMed Web of Science ®Google Scholar
• KurianSQazilbashMFayJComplete response after high-dose chemotherapy and autologous hematopoietic stem cell transplantation in metastatic breast cancer results in survival benefitBreast J200612653153517238982
   PubMed Web of Science ®Google Scholar
• KantarjianHMCortesJEO’BrienSLong-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alphaBlood200410471979198815198956
   PubMed Web of Science ®Google Scholar